AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

The approval allows the company to market Imfinzi 120 mg/2.4 ml and 500 mg/10 ml in combination with gemcitabine and ...

In March, the company had received approval from the drug regulator to import and sell sodium zirconium cyclosilicate powder ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

To meet that, ASML’s order intake needs to pick up significantly, so there are some short-term headwinds." Shares in MP ...

DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives; namely, ...

"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications. | ...